Item 2.02 Results of Operations and Financial Condition.

On August 11, 2021, Inozyme Pharma, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2021. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

The following exhibit is furnished herewith:





       Exhibit
       Number                           Description

       99.1        Press Release issued by the Company on August 11, 2021

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses